nach oben

20.02.2024 | Review

Anti-amyloid Antibody Therapies for Alzheimer’s Disease

verfasst von: Kyung Won Park

Erschienen in: Nuclear Medicine and Molecular Imaging

Einloggen, um Zugang zu erhalten

Abstract

Alzheimer’s disease (AD) is the most common cause of dementia, which is characterized by a progressive neurodegenerative disorder that is extremely difficult to treat and severely reduces quality of life. Amyloid beta (Aβ) has been the primary target of experimental therapies owing to the neurotoxicity of Aβ and the brain Aβ load detected in humans by amyloid positron emission tomography (PET) imaging. Recently completed phase 2 and 3 trials of third-generation anti-amyloid immunotherapies indicated clinical efficacy in significantly reducing brain Aβ load and inhibiting the progression of cognitive decline. Anti-amyloid immunotherapies are the first effective disease-modifying therapies for AD, and aducanumab and lecanemab were recently approved through the US Food and Drug Administration’s accelerated approval pathway. However, these therapies still exhibit insufficient clinical efficacy and are associated with amyloid-related imaging abnormalities. Further advances in the field of AD therapeutics are required to revolutionize clinical AD treatment, dementia care, and preventive cognitive healthcare.

Prince M, Wimo A, Guerchet M, Ali G, Wu Y, Prina M. World Alzheimer report–the global impact of dementia; 2015

Cummings J, Lee G, Nahed P, Kambar MEZN, Zhong K, Fonseca J, et al. Alzheimer’s disease drug development pipeline: 2022. Alzheimers Dement (N Y). 2022;8:e12295. https://doi.org/10.1002/trc2.12295.CrossRefPubMed

Klein G, Delmar P, Voyle N, Rehal S, Hofmann C, Abi-Saab D, et al. Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis. Alzheimers Res Ther. 2019;11:101. https://doi.org/10.1186/s13195-019-0559-z.CrossRefPubMedPubMedCentral

Lowe SL, Duggan Evans C, Shcherbinin S, Cheng YJ, Willis BA, Gueorguieva I, et al. Donanemab (LY3002813) phase 1b study in Alzheimer’s disease: rapid and sustained reduction of brain amyloid measured by florbetapir F18 imaging. J Prev Alzheimers Dis. 2021;8:414–24. https://doi.org/10.14283/jpad.2021.56.CrossRefPubMed

Panza F, Lozupone M, Solfrizzi V, Sardone R, Piccininni C, Dibello V, et al. BACE inhibitors in clinical development for the treatment of Alzheimer’s disease. Expert Rev Neurother. 2018;18:847–57. https://doi.org/10.1080/14737175.2018.1531706.CrossRefPubMed

Viola KL, Bicca MA, Bebenek AM, Kranz DL, Nandwana V, Waters EA, et al. The therapeutic and diagnostic potential of amyloid beta oligomers selective antibodies to treat Alzheimer’s disease. Front Neurosci. 2021;15:768646. https://doi.org/10.3389/fnins.2021.768646.CrossRefPubMed

De Felice FG, Wu D, Lambert MP, Fernandez SJ, Velasco PT, Lacor PN, et al. Alzheimer’s disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers. Neurobiol Aging. 2008;29:1334–47. https://doi.org/10.1016/j.neurobiolaging.2007.02.029.CrossRefPubMed

Rudinskiy N, Fuerer C, Demurtas D, Zamorano S, De Piano C, Herrmann AG, et al. Amyloid-beta oligomerization is associated with the generation of a typical peptide fragment fingerprint. Alzheimers Dement. 2016;12:996–1013. https://doi.org/10.1016/j.jalz.2016.03.011.CrossRefPubMed

Massaad CA, Klann E. Reactive oxygen species in the regulation of synaptic plasticity and memory. Antioxid Redox Signal. 2011;14:2013–54. https://doi.org/10.1089/ars.2010.3208.CrossRefPubMedPubMedCentral

10.

Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B. Ann Neurol. 2004;55:306–19. https://doi.org/10.1002/ana.20009.CrossRefPubMed

11.

Wang J, Jin C, Zhou J, Zhou R, Tian M, Lee HJ, et al. PET molecular imaging for pathophysiological visualization in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2023;50:765–83. https://doi.org/10.1007/s00259-022-05999-z.CrossRefPubMed

12.

Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992;256:184–5. https://doi.org/10.1126/science.166067.ADSCrossRefPubMed

13.

Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med. 2016;8:595–608. https://doi.org/10.15252/emmm.201606210.CrossRefPubMedPubMedCentral

14.

Sperling R, Mormino E, Johnson K. The evolution of preclinical Alzheimer’s disease: implications for prevention trials. Neuron. 2014;84:608–22. https://doi.org/10.1016/j.neuron.2014.10.038.CrossRefPubMedPubMedCentral

15.

Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14:535–62. https://doi.org/10.1016/j.jalz.2018.02.018.CrossRefPubMedPubMedCentral

16.

Wilcock DM, Colton CA. Anti-amyloid-β immunotherapy in Alzheimer’s disease: relevance of transgenic mouse studies to clinical trials. J Alzheimers Dis. 2008;15:555–69. https://doi.org/10.3233/jad-2008-15404.CrossRefPubMedPubMedCentral

17.

Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology. 2003;61:46–54. https://doi.org/10.1212/01.wnl.0000073623.84147.a8.CrossRefPubMed

18.

Lacosta AM, Pascual-Lucas M, Pesini P, Casabona D, Pérez-Grijalba V, Marcos-Campos I, et al. Safety, tolerability and immunogenicity of an active anti-Abeta (40) vaccine (ABvac40) in patients with Alzheimer’s disease: a randomised, doubleblind, placebo-controlled, phase I trial. Alzheimers Res Ther. 2018;10:12. https://doi.org/10.1186/s13195-018-0340-8.CrossRefPubMedPubMedCentral

19.

Wang CY, Wang PN, Chiu MJ, Finstad CL, Lin F, Lynn S, et al. UB-311, a novel UBITh®amyloid beta peptide vaccine for mild Alzheimer’s disease. Alzheimers Dement (N Y). 2017;3:262–72. https://doi.org/10.1016/j.trci.2017.03.005.CrossRefPubMed

20.

Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, et al. Passive immunotherapy against Aβ in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation. 2004;1:24. https://doi.org/10.1186/1742-2094-1-24.CrossRefPubMedPubMedCentral

21.

Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, et al. Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer’s disease-like neuropathology. Proc Natl Acad Sci U S A. 2003;100:2023–8. https://doi.org/10.1073/pnas.0436286100.ADSCrossRefPubMedPubMedCentral

22.

Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Alamed J, et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci. 2004;24:6144–51. https://doi.org/10.1523/JNEUROSCI.1090-04.2004.CrossRefPubMedPubMedCentral

23.

Hartman RE, Izumi Y, Bales KR, Paul SM, Wozniak DF, Holtzman DM. Treatment with an amyloid-β antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer’s disease. J Neurosci. 2005;25:6213–20. https://doi.org/10.1523/JNEUROSCI.0664-05.2005.CrossRefPubMedPubMedCentral

24.

Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of Bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370:322–33. https://doi.org/10.1056/NEJMoa1304839.CrossRefPubMedPubMedCentral

25.

Chapleau M, Iaccarino L, Soleimani-Meigooni D, Rabinovici GD. The role of amyloid PET in imaging neurodegenerative disorders: a review. J Nucl Med. 2022;63;Suppl 1:13S–9S–S19. https://doi.org/10.2967/jnumed.121.263195

26.

Lendel C, Bjerring M, Dubnovitsky A, Kelly RT, Filippov A, Antzutkin ON, et al. A hexameric peptide barrel as building block of amyloid-β protofibrils. Angew Chem Int Ed Engl. 2014;53:12756–60. https://doi.org/10.1002/anie.201406357.CrossRefPubMed

27.

Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, et al. Trial of solanezumab for mild dementia due to Alzheimer’s disease. N Engl J Med. 2018;378:321–30. https://doi.org/10.1056/NEJMoa1705971.CrossRefPubMed

28.

Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370:311–21. https://doi.org/10.1056/NEJMoa1312889.CrossRefPubMed

29.

Meilandt W, Maloney J, Imperio J, Bainbridge T, Reichelt M, Mandikian D, et al. Characterization of the selective in vivo and in vitro binding properties of crenezumab: insights into crenezumab’s unique mechanism of action. Alzheimers Res Ther. 2019;11:97. https://doi.org/10.1186/s13195-019-0553-5.CrossRefPubMedPubMedCentral

30.

Cummings JL, Cohen S, van Dyck CH, Brody M, Curtis C, Cho W, et al. ABBY: a phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease. Neurology. 2018;90:e1889–97. https://doi.org/10.1212/WNL.0000000000005550.CrossRefPubMedPubMedCentral

31.

Ostrowitzki S, Bittner T, Sink KM, Mackey H, Rabe C, Honig LS, et al. Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease: two phase 3 randomized placebo-controlled trials. JAMA Neurol. 2022;79:1113–21. https://doi.org/10.1001/jamaneurol.2022.2909.CrossRefPubMedPubMedCentral

32.

Reiman EM, Pruzin JJ, Rios-Romenets S, Brown C, Giraldo M, Acosta-Baena N, et al. A public resource of baseline data from the Alzheimer’s prevention initiative autosomal-dominant Alzheimer’s disease trial. Alzheimers Dement. 2023;19:1938–46. https://doi.org/10.1002/alz.12843.CrossRefPubMed

33.

Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease. Alzheimers Res Ther. 2017;9:95. https://doi.org/10.1186/s13195-017-0318-y.CrossRefPubMedPubMedCentral

34.

Bateman RJ, Cummings J, Schobel S, Salloway S, Vellas B, Boada M, et al. Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease. Alzheimers Res Ther. 2022;14:178. https://doi.org/10.1186/s13195-022-01110-8.CrossRefPubMedPubMedCentral

35.

Roche announces results from the GRADUATE Phase III trials of gantenerumab; 2022. https://www.roche.com/media/releases/med-cor-2022-11-14. Accessed 11/08/2023

36.

Arndt JW, Qian F, Smith BA, Quan C, Kilambi KP, Bush MW, et al. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β. Sci Rep. 2018;8:6412. https://doi.org/10.1038/s41598-018-24501-0.ADSCrossRefPubMedPubMedCentral

37.

Colvin MT, Silvers R, Ni QZ, Can TV, Sergeyev I, Rosay M, et al. Atomic resolution structure of monomorphic Aβ42 amyloid fibrils. J Am Chem Soc. 2016;138:9663–74. https://doi.org/10.1021/jacs.6b05129.CrossRefPubMedPubMedCentral

38.

Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature. 2016;537:50–6. https://doi.org/10.1038/nature19323.ADSCrossRefPubMed

39.

Um JW, Kaufman AC, Kostylev M, Heiss JK, Stagi M, Takahashi H, et al. Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer aβ oligomer bound to cellular prion protein. Neuron. 2013;79:887–902. https://doi.org/10.1016/j.neuron.2013.06.036.CrossRefPubMedPubMedCentral

40.

Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. J Prev Alzheimers Dis. 2022;9:197–210. https://doi.org/10.14283/jpad.2022.30.CrossRefPubMed

41.

Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, Purcell D, et al. Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol. 2022;79:13–21. https://doi.org/10.1001/jamaneurol.2021.4161.CrossRefPubMed

42.

Beshir SA, Aadithsoorya AM, Parveen A, Goh SSL, Hussain N, Menon VB. Aducanumab therapy to treat Alzheimer’s disease: a narrative review. Int J Alzheimers Dis. 2022;2022:9343514. https://doi.org/10.1155/2022/9343514.CrossRefPubMedPubMedCentral

43.

Basun H, Bogdanovic N, Ingelsson M, Almkvist O, Näslund J, Axelman K, et al. Clinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer disease. Arch Neurol. 2008;65:499–505. https://doi.org/10.1001/archneur.65.4.499.CrossRefPubMedPubMedCentral

44.

Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, et al. The ‘Arctic’ APP mutation (E693G) causes Alzheimer’s disease by enhanced abeta protofibril formation. Nat Neurosci. 2001;4:887–93. https://doi.org/10.1038/nn0901-887.CrossRefPubMed

45.

van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388:9–21. https://doi.org/10.1056/NEJMoa2212948.CrossRefPubMed

46.

Papp KV, Rentz DM, Orlovsky I, Sperling RA, Mormino EC. Optimizing the preclinical Alzheimer’s cognitive composite with semantic processing: the PACC5. Alzheimers Dement (N Y). 2017;3:668–77. https://doi.org/10.1016/j.trci.2017.10.004.CrossRefPubMed

47.

Jawhar S, Wirths O, Bayer TA. Pyroglutamate amyloid-beta (Aβ): a hatchet man in Alzheimer disease. J Biol Chem. 2011;286:38825–32. https://doi.org/10.1074/jbc.R111.288308.CrossRefPubMedPubMedCentral

48.

Iwatsubo T, Saido TC, Mann DM, Lee VM, Trojanowski JQ. Full-length amyloid-beta (1–42 (43)) and amino-terminally modified and truncated amyloid-beta 42 (43) deposit in diffuse plaques. Am J Pathol. 1996;149:1823–30.PubMedPubMedCentral

49.

Demattos RB, Lu J, Tang Y, Racke MM, Delong CA, Tzaferis JA, et al. A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer’s disease mice. Neuron. 2012;76:908–20. https://doi.org/10.1016/j.neuron.2012.10.029.CrossRefPubMed

50.

Espay AJ. Donanemab in early Alzheimer’s disease. N Engl J Med. 2021;385:666–7. https://doi.org/10.1056/NEJMc2109455.CrossRefPubMed

51.

Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, et al. Donanemab in early Alzheimer’s disease. N Engl J Med. 2021;384:1691–704. https://doi.org/10.1056/NEJMoa2100708.CrossRefPubMed

52.

Shcherbinin S, Andersen SW, Evans CD, Lo AC, Lu M, Navitsky M, et al. TRAILBLAZER-ALZ Study: dynamics of amyloid reduction after donanemab treatment. Alzheimers Dement. 2021;17:e057492. https://doi.org/10.1002/alz.057492.CrossRef

53.

Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330:512–27. https://doi.org/10.1001/jama.2023.13239.CrossRefPubMedPubMedCentral

54.

Jin Y. Safety and amyloid plaque reduction effects of remternetug in patients with Alzheimer’s disease: interim analysis from a phase 1 study AD/PD Conference. Sweden: Gothernburg; 2023. p. 2023.

55.

Siemers E, Hitchcock J, Sundell K, Dean R, Jerecic J, Cline E, et al. ACU193, A monoclonal antibody that selectively binds soluble Aβ oligomers: development rationale, phase 1 trial design, and clinical development plan. J Prev Alzheimers Dis. 2023;10:19–24. https://doi.org/10.14283/jpad.2022.93.CrossRefPubMed

56.

ALZFORUM. Trontinemab: AlzForum Foundation Inc.; 2023. https://www.alzforum.org/therapeutics/trontinemab. Accessed 11/08/2023

57.

Yadollahikhales G, Rojas JC. Anti-amyloid immunotherapies for Alzheimer’s disease: a 2023 clinical update. Neurotherapeutics. 2023;20:914–31. https://doi.org/10.1007/s13311-023-01405-0.CrossRefPubMedPubMedCentral

Titel: Anti-amyloid Antibody Therapies for Alzheimer’s Disease
verfasst von: Kyung Won Park
Publikationsdatum: 20.02.2024
Verlag: Springer Nature Singapore
Erschienen in: Nuclear Medicine and Molecular Imaging
Print ISSN: 1869-3474
Elektronische ISSN: 1869-3482
DOI: https://doi.org/10.1007/s13139-024-00848-3

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten